Mariana Purice, I.H. Ursu, A. Goldstein

Slides:



Advertisements
Similar presentations
Subclinical Thyroid Disease
Advertisements

Diabetes and Hypothyroidism
Retinol Binding Protein-4 levels in thyroid overt and subclinical dysfunction Kokkinos Spiridon, Tiaka Elisavet, Manolakis Anastasios, Papanas Nikolaos,
Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.
A raised thyroid stimulating hormone result is associated with an increased rate of cardiovascular events and would benefit from treatment Gibbons V, Conaglen.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Vishnugirish,Dr.Somashekar, *Dr.Chandrika Rao M.S.Ramaiah Medical College and Hospital Bangalore. ‘Cognitive performance and thyroid hormone levels in.
Mary Hannon-Fletcher Micronutrient supplementation in haemodialysis patient enhances folate levels and reduces homocysteine 4th Annual Translational Medicine.
Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial นศภ. ณัฐวุฒิ ดวงแดง มหาวิทยาลัยเชียงใหม่
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
Can Folic Acid Prevent AMD? Rick Trevino, OD Evansville VA Clinic
HYPOTHYROIDISM. INTRODUCTION  Hypothyroidism is defined as a deficiency in thyroid hormone secretion and action that produces a variety of clinical signs.
  The thyroid gland The thyroid gland is a small butterfly-shaped gland at the base of the neck. It weighs only about 20 grams. However, the hormones.
Interferences in hormones imunoassays Facts and Traps Mariana Purice, Andra Caragheorgheopol, Cristina Perhaita, Ecaterina Dumitriu, Florin Alexiu, Corin.
Presented by : Fawziya Alyafei ped endocrine fellow ped endocrine fellow Department of Pediatrics Endocrinology and Hematology Hamad Medical Center, Qatar.
231 Unusual coexistence of differentiated thyroid cancer and thyrotropin- producing pituitary microadenoma: a case report 1 Muni A., 1 Rouhanifar H., 1.
Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Colorado Thyroid Disease Prevalence Study Arch.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Osteopenia in Sheehan’s Syndrome
Protein thiol (µmol/L)
Diabetes Journal Club Carina Signori 1/19/2012
The ALERT Trial.
W Tormey6, CJ Thompson1, D Smith1, A Agha1.
The Plasma Concentrations of Atorvastatin and its Active Metabolites in Relation to the Dose in Stable Coronary Artery Disease Patients at a Tertiary Referral.
Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:
Hypothyroidism during pregnancy
Treatment with rosuvastatin for severe dyslipidaemia in patients with schizophrenia and schizoaffective disorder M De Hert1, D Kalnicka1, R van Winkel1,
GLYPICAN-4 LEVELS IN RELATION WITH HORMONAL AND METABOLIC PROFILE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME Doç.Dr.Özlem ALTINKAYA.
Adiponectin Correlation With Plasma Lipoprotein Subclasses Determined By NMR And With The Risk Of Venous Thrombosis. Fernández JA, Deguchi H, Pecheniuk.
Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic.
Non-metabolic syndrome mean (DS) Metabolic syndrome mean (DS)
Rambam health care campus, Haifa, Israel
Poster Number 2842 Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus.   L. Durcan1, A.
Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.
Hypothyroidism management
Dr. Syed Waleem Pasha Assistant Professor Yenepoya Medical College
Fig. 1. Serum total cholesterol (A), LDL cholesterol (B), triglyceride (C) and HDL cholesterol level (D) according to HBsAg status in age group. Total.
Coagulation/Fibrinolytic Factors in PCOS
HOPE: Heart Outcomes Prevention Evaluation study
Miss.Shuchismita Behera Miss.Sujata Dixit Dr.G.Bulliyya Dr.S.K.Kar
LIPID PROFILE OF EARLY RHEUMATOID ARTHRITIS PATIENTS
Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:
Transient hypothyroidism in 1-month-old boy born at 36 weeks and weighing 2440 g. Neonatal screening revealed abnormally high thyroid stimulating hormone.
Relationship between Thyroid Stimulating hormone and Antioxidant Status in Patients with Suspected Thyroid Dysfunction   A. M. S. M. Wickramarathne1,2*,
Square-root TSH (μIU/mL) Presence vs. Absence TPO Abᵈ
HDL cholesterol and cardiovascular risk Epidemiological evidence
First time a CETP inhibitor shows reduction of serious CV events
Classification of total cholesterol levels
From the Indianapolis – Ibadan Dementia Research Project.
These slides highlight a cardiology grand rounds and cardiology research rounds presented by William James Howard, MD at St. Michael’s Hospital, in Toronto,
Baseline characteristics of HPS participants by prior diabetes
A: Epidemiology update
Applying for EU FP7 research funding
Section 7: Aggressive vs moderate approach to lipid lowering
Hypertension evaluation
1 2 The Good, Bad, Ugly and Deadly.
Rational Order of Laboratory Tests in Cardiovascular Diseases
LRC-CPPT and MRFIT Content Points:
Major classes of drugs to reduce lipids
Switch to DTG-containing regimen
NGM282 in NASH: 3 mg QD (phase 2)
METABOLIC CHANGES AFTER VIRAL ERADICATION IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION Tudor Cuciureanu1,2, Laura Huiban1,2, Stefan Chiriac1,2.
Thyroid hormones.
HYPOTHYROIDISM.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Mariana Purice, I.H. Ursu, A. Goldstein National Institute of Endocrinology “C.I. Parhon”, Bucharest, Romania HYPERHOMOCYSTEINEMIA, A RISK FACTOR INTERACTING IN MODERATE AND SEVER HYPOTHYROIDISM 1. Thyroid status is an important determinant of plasma tHcy and affects serum folate levels . 2. Significantly lower serum folate in the study group is pleading for the role of folate deficiency in hyperhomocysteinemia induced by hypothyroidism. 3. High prevalence of hyperhomocysteinemia in hypothyroid patients represent an argument to associate folate supplementation to levothyroxine therapy, especially in patients with other risk factors for cardiovascular disease. 4. Dynamic evaluation of plasmatic homocysteine levels in correlation with Folic Acid and standard laboratory parameters is important for the estimation of supplementary risk factor and follow up of the specific therapy in hypothyroid patients. CONCLUSIONS DISCUSSION Moderate hyperhomocysteinemia was frequent in our study groups: 68% in group 1 and 76% in group 2. Borderline (10-12 µmol/L) values were found in 24 % in group 1 and 28 % in group 2. Mean serum folate was significantly lower in group 1 versus control (5.9 ng/ml versus 9.1ng/ml) and NS lower in group 2 Both serum cholesterol and LDL cholesterol were significant higher in the study groups before treatment. Serum creatinine was in the normal range in both groups. After six months of folate therapy associated with levothyroxine therapy, plasma homocysteine decreased significantly in the moderate hypothyroid patients from 14.27 µmol/L to 8.17 and from 16.9 to 7.9 in the sever iatrogenic hypothyroidism. Epidemiologic evidences show that mild hyperhomocysteinemia (>12 μmol/L) is an independent risk factor for atherosclerotic and atherothrombotic vascular disease. Between 5-10 % of normal population and more then 40% of patients with cardiovascular diseases have hyperhomocysteinemia (HHcy). Additional risk factors and endocrine disorders (diabetes, hypothyroidism) may additively or by interacting with hyperhomocysteinemia, increase overall risk. Hypothyroidism is associated with increased cardiovascular morbidity which might be explained by the atherogenic lipid profile and/or hyperhomocysteinemia. This may exacerbate the risk of cardiovascular disease in hypothyroidism that is traditionally attributed to lipid changes. Study groups: 25 patients with primary hypothyroidism before and during levotyroxine treatment. We measured plasma tHcy , serum folate, TSH, T3, T4 and cholesterol, LDL, HDL, , creatinine. We found moderate low level of serum folate (5.84 ng/ml) .Only 20% of subjects had basal tHcy < 10 μmol/L while 44% had plasma tHcy between 10-17 μmol/L and 36 % had tHcy >17 μmol /L, significant elevated cholesterol, HDL cholesterol at medium risk level . Mean TSH concentration was 24.88 μUI/ml. After achieving an euthyroid status, tHcy, folate and hormons leveles were evaluated before and after three and six month of daily folate supplementation therapy (5 mg/day). In 76% of the subjects with basal level t Hcy> 10 μmol/lL, a significant decrease (p<0.001) was achieved in correlation with normalization of TSH and cholesterol levels. 25 patients with postoperative hypothyroidism after thyroidectomy for thyroid cancer. Before radioiodine therapy, they discontinued levotyroxine substitution during 6 weeks. With mean TSH concentration of 29.9 μU/ml and mean cholesterol of 310.92 mg/ml , we considered them in a sever hypothyroidism state. The tHct was 17.69 ± 3.93 μmol/L significantly higher then for control group (p< 0.001). Only 24% had tHcy < 10 μmol/L, while 28% had tHcy: 15-20 μmol/L and 48% had tHcy > 20μmol/L. High values of tHcy was correlated with high levels of thyroglobuline (> 2 ng/ml) for 10 patients with thyroid cancer metastasis. Normal folate serum mean level was found (7.89 ng/ml). Carotidian ultrasound for measuring the intima - media thickness (IMT) was done. We evaluated the patients after 3 month and 6 month of folic acid administration (5 mg/day) together with levotyroxine substitution, observing significant decrease of tHcy (p<0.002) while IMT remained almost unchanged. ABSTRACT INTRODUCTION Moderately elevated plasma homocysteine is highly prevalent in the general population, being a risk factor for cardiovascular disease and is caused by hormonal, nutritional and genetic factors. The elevated plasma homocysteine may exacerbate the risk of cardiovascular disease in hypothyroidism that is traditionally attributed to lipid changes. Aims of Study 1. Evaluate the prevalence of moderate hyerhomocysteinemia and of borderline values (10-12 µmol/L ) in hypothyroid patients and in thyroidectomized patients for thyroid cancer before L-Thyroxine treatment 2. Evaluate the effect of Folic Acid supplementation in patients with plasma homocysteine over 10 µmol/L. 3. Evaluate the prevalence of concomitant increase plasma homocysteine and serum lipids as vascular risk factors in hypothyroid patients before levothyroxine treatment. METHODS STUDY GROUPS Group Thyroid Status n Gender Age Basal TSH Therapy Group1: Moderate Hypothyroidism 25 F=23 M=2 52-80 >10 µIU/ml Levo thyroxine: 75-150 µg/day Folic acid : 5 mg/day Group 2: Sever Hypothyroidism postoperative hypothyroidism after thyroidectomy for thyroid cancer before radiotherapy. F=20 M=5 52-73 >50 µIU/ml Levo thyroxine: 100-150 µg/day Folic acid: 5 mg/day Control euthyroid status 32 M=12 35-50 2.2 µIU/ml Total homocysteine ( tHcy) was assayed with ELISA method(DRG) after a reduction and enzymatic conversion steps . Reference values tHcy < 10 µmol/L SAFE tHcy : 10-12 µmol/L Tolerated: normal subjects Therapy recommended (ac folic +/- Vit B) for subjects with high risk factors tHcy : > 12-30 µmol/L moderate Hyperhomocysteinemy tHcy : > 30-100 µmol/L intermediate Hyperhomocysteinemy tHcy : > 100 µmol/L sever Hyperhomocysteinemia Folic acid: chemiluminiscence, ACS -180 Bayer Serum cholesterol, HDL, LDL, creatinine: colorimetric (Roche, HITACHI 912) Serum hormones : TSH, T3, T4, FT4 ( RIA/ IRMA, ADALTIS) Results were subjected to non parametric tests (Mann-Whitney U test) and data are expressed as media+/- SD. Correlations were tested by Spearman correlation test All statistical procedure were performed using the SPSS ( for Social Sciences Statistical Package). Statistical analysis After therapy RESULTS GROUP 2 Fig. 4. Homocystein concentration distribution 24% 28% 48% tHcy<10 mol/l tHcy: 10-12 mol/l tHcy > 20 mol/l Fg. 6. Serum colesterol, HDL and LDL before treatment Fg. 5. Homocystein and Folic acid before treatment GROUP 1 Fig.3. Homocystein and Folic acid levels in group 1 and control 2 4 6 8 10 12 14 16 Hcy FolicAcid 9.32 11.9 14.27 5.81 Hypothyr Before therapy GROUP 1 GROUP 2